Market Share, Analysis, and Forecast for Global Actinic Keratosis Treatment by 2031

(MENAFN– Straits Research)
Introduction

Treating actinic keratosis, a skin condition caused by sun exposure, aims to prevent these lesions from developing into skin cancer. Treatment options include topical medications, cryotherapy, curettage, electrodesiccation, photodynamic therapy (PDT), and laser therapy. Lotions or gels containing fluorouracil, imiquimod, ingenol mebutate, or diclofenac target abnormal cells directly. “Curettage” and “electrification” involve removing damaged skin with a curette and destroying remaining abnormal cells by electrically searing the area.

Photodynamic therapy applies a photosensitizing agent to the affected area, which, when activated by specific wavelengths of light, kills abnormal cells. Laser therapy targets and eliminates only defective cells. Various factors, such as the patient’s health, number and thickness of lesions, and recommended treatment, must be considered when deciding on the treatment plan. Regular check-ups and UV protection are essential for preventing actinic keratosis recurrence and reducing skin cancer risk.

Market Dynamics
Rise in Prevalence of Actinic Keratosis Drives the Global Market

The increasing prevalence of conditions leading to actinic keratosis is expected to drive demand for treatments. More than 58 million Americans are affected by actinic keratosis, according to the Skin Cancer Foundation. The incidence of actinic keratosis in the US is around 10.2% in females and 26.5% in males, indicating a gender disparity. This information was collected through a survey.

With the rise in actinic keratosis cases, the demand for topical treatments for the condition is predicted to increase, thereby boosting the global market.

Growth Opportunities in Emerging Markets
Create Tremendous Opportunities

Growth in emerging markets is expected due to improved pharmaceutical infrastructure, increased pharmaceutical companies, and higher demand for actinic keratosis treatments. The healthcare industry in emerging countries is growing rapidly, driven by investments in healthcare infrastructure and advanced manufacturing systems. The rising incidence of actinic keratosis in countries like Australia and New Zealand presents growth opportunities for the market.

Regional Analysis

North America dominates the global actinic keratosis treatment market and is forecasted to grow at a CAGR of 3.4%. Factors contributing to this growth include increased demand for actinic keratosis treatments, advanced healthcare facilities, and ongoing R&D projects for new therapies.

Europe is expected to grow at a CAGR of 4.2%, driven by advanced treatment products, demand for actinic keratosis treatments, expanding patient population, pharmaceutical industry infrastructure, and availability of specialists.

Key Highlights

• The global actinic keratosis treatment market was valued at USD 6.42 billion in 2022 and is projected to reach USD 9.22 billion by 2031, growing at a CAGR of 4.1%.
• Fluorouracil is the dominant drug type in the market, with a projected CAGR of 3.8%.
• The prescription segment leads the market and is expected to grow at a CAGR of 4.3%.
• Hospital pharmacies have the highest market share and are predicted to grow at a CAGR of 4.3%.
• North America is the largest market shareholder with a CAGR of 3.4%.

Competitive Players